Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
2.41
Dollar change
+0.06
Percentage change
2.55
%
IndexRUT P/E- EPS (ttm)-1.36 Insider Own24.20% Shs Outstand56.52M Perf Week-9.06%
Market Cap139.85M Forward P/E- EPS next Y-1.22 Insider Trans-1.59% Shs Float42.89M Perf Month-26.75%
Income-73.10M PEG- EPS next Q-0.31 Inst Own75.31% Short Float13.84% Perf Quarter-57.42%
Sales0.00M P/S- EPS this Y30.85% Inst Trans4.94% Short Ratio5.04 Perf Half Y-53.56%
Book/sh1.72 P/B1.40 EPS next Y5.93% ROA-47.12% Short Interest5.94M Perf Year1.69%
Cash/sh1.94 P/C1.24 EPS next 5Y- ROE-63.09% 52W Range2.23 - 7.66 Perf YTD-14.23%
Dividend Est.- P/FCF- EPS past 5Y-49.79% ROI-62.43% 52W High-68.54% Beta2.48
Dividend TTM- Quick Ratio5.55 Sales past 5Y0.00% Gross Margin- 52W Low8.07% ATR (14)0.19
Dividend Ex-Date- Current Ratio5.55 EPS Y/Y TTM35.89% Oper. Margin- RSI (14)35.53 Volatility6.20% 6.95%
Employees54 Debt/Eq0.24 Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price14.50
Option/ShortYes / Yes LT Debt/Eq0.20 EPS Q/Q39.04% Payout- Rel Volume0.42 Prev Close2.35
Sales Surprise- EPS Surprise24.99% Sales Q/Q- EarningsNov 05 BMO Avg Volume1.18M Price2.41
SMA20-9.81% SMA50-22.02% SMA200-49.26% Trades Volume495,918 Change2.55%
Date Action Analyst Rating Change Price Target Change
Jul-31-24Initiated Raymond James Outperform $20
Jul-14-23Initiated Piper Sandler Overweight
Jun-30-23Upgrade Stifel Hold → Buy $2 → $10
Jun-28-23Upgrade H.C. Wainwright Neutral → Buy $11
Jun-27-23Upgrade Wedbush Neutral → Outperform $10
Mar-29-22Downgrade Wedbush Outperform → Neutral
Mar-22-22Downgrade H.C. Wainwright Buy → Neutral
Sep-30-21Initiated Stifel Hold $10
Jan-07-21Initiated Wedbush Outperform $45
Nov-24-20Initiated Berenberg Buy $58
Nov-05-24 09:00AM
08:00AM
Nov-01-24 08:00AM
Oct-07-24 04:01PM
Sep-23-24 11:43AM
07:00AM Loading…
07:00AM
Sep-22-24 10:00AM
Sep-14-24 03:30AM
Aug-08-24 04:05PM
12:00PM
Aug-06-24 01:53PM
07:37AM
07:30AM
Jun-29-24 08:28PM
06:30PM
10:00AM Loading…
Jun-01-24 10:00AM
May-29-24 08:00AM
May-16-24 08:23AM
May-10-24 08:46AM
May-09-24 01:54PM
07:30AM
07:28AM
Apr-29-24 08:50AM
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
Apr-08-24 09:55AM
Apr-07-24 06:00PM
08:00AM Loading…
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 04:30PM
May-11-22 04:30PM
Apr-28-22 12:52PM
Apr-25-22 09:00AM
Apr-18-22 07:00AM
Apr-07-22 04:30PM
07:00AM
Mar-17-22 05:00PM
Mar-02-22 08:00AM
Feb-22-22 08:00AM
Feb-16-22 05:28AM
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Versant Venture Capital VI, L.10% OwnerAug 28 '24Sale6.32221,6001,400,5563,726,341Aug 30 04:16 PM
David EpsteinFormer EmployerJul 31 '24Proposed Sale6.2050,000310,000Jul 31 04:18 PM
David EpsteinFormer EmployeeJul 26 '24Proposed Sale6.2050,000310,000Jul 26 05:54 PM